GC Biopharma headquarters in Yongin, Gyeonggi Province.
Korea’s GC Biopharma said Friday its first-quarter operating profit rose 46.3 percent from a year earlier, helped by strong growth of Alyglo, its blood plasma-derived therapy.
Operating profit came in at 11.7 billion won ($7.9 million) for the January-to-March period, while revenue rose 13.5 percent to 435.5 billion won on a consolidated basis, the company said in a regulatory filing. Net profit was 20.1 billion won.
Alyglo recorded 34.9 billion won in first-quarter sales, about four times higher than a year earlier.
The company said uncertainty around its U.S. business had eased after plasma-derived therapies were included among products exempted from U.S. tariff measures announced in April.
GC Biopharma is also moving to strengthen its plasma supply chain in the United States.
Its U.S. plasma center subsidiary, ABO Plasma, recently received FDA approval for its Laredo, Texas, center, a step the company said would support plasma sales and improve supply stability. It also plans to open a plasma center in Eagle Pass, Texas, this year.
On a standalone basis, GC Biopharma posted 114.9 billion won in plasma-derived product sales, 56.8 billion won in vaccine sales, 81.6 billion won in prescription drug sales and 32.4 billion won in over-the-counter and consumer healthcare sales.
Kim Ji-hye
댓글
0